

Novartis announces five-year data that reinforce the safety and efficacy profile of Aimovig® (erenumab-aooe) in adult patients with episodic migraine

Oct 03, 2020

Source URL: <https://prod1.novartis.com/us-en/news/media-releases/novartis-announces-five-year-data-reinforce-safety-and-efficacy-profile-aimovig-erenumab-aooe-adult-patients-episodic-migraine-0>

List of links present in page

1. <https://prod1.novartis.com/us-en/us-en/news/media-releases/novartis-announces-five-year-data-reinforce-safety-and-efficacy-profile-aimovig-erenumab-aooe-adult-patients-episodic-migraine-0>